BMRN — Biomarin Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00
- $16.06bn
- $16.08bn
- $2.42bn
- 84
- 13
- 44
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -23.8 | 859 | -64.1 | 142 | 168 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 151 | 234 | 210 | 80.8 | 269 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -101 | -224 | 66 | -96.4 | -337 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 48.3 | 85.4 | 305 | 176 | 159 |
Capital Expenditures | -163 | -138 | -119 | -132 | -108 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 132 | 83.9 | -247 | 112 | -3.63 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -31 | -53.6 | -366 | -20 | -111 |
Financing Cash Flow Items | -101 | -44.6 | -46.2 | -85.4 | -85.8 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -74.7 | 181 | -0.048 | -18.6 | -18.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -56.5 | 212 | -61.9 | 137 | 30.6 |